Lakefront Biotherapeutics NV current report, Q1 FY2026

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV, a foreign private issuer, for the month of March 2026. The filing incorporates by reference a press release dated March 17, 2026 (Exhibit 99.1). The registrant's principal executive office is located in Mechelen, Belgium. The filing references multiple Registration Statements on Form S-8.

Note: The input metadata lists "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as "Galapagos NV."

Key Financial Metrics

The filing text provided does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.

Material Changes

The filing text does not provide details on material changes versus prior periods. The document serves primarily to incorporate a press release by reference, the content of which is not included in the provided text.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or descriptions of unusual items. These details would be contained within the attached Exhibit 99.1 (Press Release), which is not present in the source text.

Investor Verification Checklist

  • Verify the actual content of the press release dated March 17, 2026 (Exhibit 99.1), as the summary relies entirely on this incorporated document.
  • Confirm the discrepancy between the metadata company name ("Lakefront Biotherapeutics NV") and the filing registrant ("Galapagos NV").
  • Review the referenced Form S-8 Registration Statements for details on equity compensation plans if relevant to the press release.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.